Long-term cardiovascular mortality risk in patients with bladder cancer: a real-world retrospective study of 129,765 cases based on the SEER database

被引:3
作者
Liao, Jia [1 ]
Zhou, Zihua [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2023年 / 10卷
关键词
bladder cancer; cardiovascular mortality; cardio-oncology; SEER database; competing risk model; nomogram; EPIDEMIOLOGY; MARRIAGE; CARE;
D O I
10.3389/fcvm.2023.1142417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionAmong 28 cancer types, bladder cancer (BC) patients have the highest risk of dying from cardiovascular disease (CVD). We aimed to identify the independent risk factors and develop a novel nomogram for predicting long-term cardiovascular mortality in patients with BC.MethodsWe extracted data from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed with bladder cancer (BC) between 2000 and 2017. The cumulative incidence function (CIF) was computed for both CVD-related death and other causes of death. Then we performed univariate and multivariate analyses to explore the independent risk factors and further develop a novel nomogram to predict cardiovascular mortality at 5- and 10-year for patients with BC by using the Fine-Gray competing risk model. The efficacy of the developed nomogram was assessed by the concordance index (C-index), receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).ResultsA total of 12,9765 patients were randomly divided into training (n = 90,835, 70%), and validation (n = 38,930, 30%) cohorts. During the follow-up period, 31,862 (46.4%) patients died from BC, and 36793 (53.6%) patients died from non-BC, of which CVD-related death accounted for 17,165 (46.7%), being the major cause of non-cancer deaths. The multivariate analysis showed that age, sex, race, marital status, histologic type, tumor grade, summary stage, and chemotherapy were independent risk factors of CVD-related death in BC patients. The nomogram based on the above eight factors showed good discrimination power, excellent consistency, and clinical practicability: (1) the areas under the curve of the ROC for 5- and 10-year CVD-related death of 0.725 and 0.732 in the training cohort and 0.726 and 0.734 in the validation cohort; (2) the calibration curves showed that the prediction probabilities were basically consistent with the observed probabilities; (3) the DCA curves revealed that the nomogram had high positive net benefits.DiscussionTo our knowledge, this was the first study to identify the independent risk factors and develop a novel nomogram for predicting long-term cardiovascular mortality in patients with BC based on the competing risk model. Our results could help clinicians comprehensively and effectively manage the co-patient of BC and CVD, thereby reducing the risk of cardiovascular mortality in BC survivors.
引用
收藏
页数:13
相关论文
共 51 条
  • [1] Racial Variation in the Quality of Surgical Care for Bladder Cancer
    Barocas, Daniel A.
    Alvarez, JoAnn
    Koyama, Tatsuki
    Anderson, Christopher B.
    Gray, Darryl T.
    Fowke, Jay H.
    You, Chaochen
    Chang, Sam S.
    Cookson, Michael S.
    Smith, Joseph A., Jr.
    Penson, David F.
    [J]. CANCER, 2014, 120 (07) : 1018 - 1025
  • [2] Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence
    Barone, Biagio
    Finati, Marco
    Cinelli, Francesco
    Fanelli, Antonio
    Del Giudice, Francesco
    De Berardinis, Ettore
    Sciarra, Alessandro
    Russo, Gianluca
    Mancini, Vito
    D'Altilia, Nicola
    Ferro, Matteo
    Porreca, Angelo
    Chung, Benjamin I.
    Basran, Satvir
    Bettocchi, Carlo
    Cormio, Luigi
    Imbimbo, Ciro
    Carrieri, Giuseppe
    Crocetto, Felice
    Busetto, Gian Maria
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (03):
  • [3] Mechanisms of Coronary Thrombosis in Cigarette Smoke Exposure
    Barua, Rajat S.
    Ambrose, John A.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (07) : 1460 - 1467
  • [4] Cardio-oncology: a new medical issue
    Cardinale, D.
    Colombo, A.
    Lamantia, G.
    Colombo, N.
    Civelli, M.
    De Giacomi, G.
    Pandini, C.
    Sandri, M. T.
    Cipolla, C. M.
    [J]. ECANCERMEDICALSCIENCE, 2008, 2
  • [5] The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care
    Casey, Martin F.
    Gross, Tal
    Wisnivesky, Juan
    Stensland, Kristian D.
    Oh, William K.
    Galsky, Matthew D.
    [J]. JOURNAL OF UROLOGY, 2015, 194 (01) : 36 - 41
  • [6] Chalasani Venu, 2009, Can Urol Assoc J, V3, pS193
  • [7] A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
    Chhabra, Neeraj
    Kennedy, Joseph
    [J]. JOURNAL OF MEDICAL TOXICOLOGY, 2021, 17 (04) : 411 - 424
  • [8] Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
    Cumberbatch, Marcus George Kwesi
    Jubber, Ibrahim
    Black, Peter C.
    Esperto, Francesco
    Figueroa, Jonine D.
    Kamat, Ashish M.
    Kiemeney, Lambertus
    Lotan, Yair
    Pang, Karl
    Silverman, Debra T.
    Znaor, Ariana
    Catto, James W. F.
    [J]. EUROPEAN UROLOGY, 2018, 74 (06) : 784 - 795
  • [9] Disparities in Stage at Diagnosis in an Equal-access Integrated Delivery System: A Retrospective Cohort Study of 7244 Patients With Bladder Cancer
    Danforth, Kim N.
    Luong, Tiffany Q.
    Yi, David K.
    Yamamoto, Ayae
    Kawatkar, Aniket A.
    Kim, Philip H.
    Loo, Ronald K.
    Sidell, Margo A.
    Williams, Stephen G.
    [J]. CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E91 - E102
  • [10] Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity
    Dessalvi, Christian Cadeddu
    Deidda, Martino
    Noto, Antonio
    Madeddu, Clelia
    Cugusi, Lucia
    Santoro, Ciro
    Lopez-Fernandez, Teresa
    Galderisi, Maurizio
    Mercuro, Giuseppe
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2021, 34 (07) : 572 - 588